Evidence map›Paper›PMID 42095966›Full record

ArticleMikrochimica acta2026

Direct/enrichment dual-mode lateral flow immunoassay enabled by a composite magnetic-fluorescent nanolabel for ultrasensitive detection of Helicobacter pylori.

Tingting Huang, Ting Wu, Xuesong Xiong, Xiao Zhao, Jiahuan Zhang, Chongwen Wang, Bing Gu, Jiansong Gu, Fen Li

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tingting Huang *The Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliate to Yangzhou University, Huai'an, Jiangsu Province, 223001, China.
Ting Wu *Department of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510000, China.
Xuesong Xiong *The Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliate to Yangzhou University, Huai'an, Jiangsu Province, 223001, China.
Xiao ZhaoThe Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliate to Yangzhou University, Huai'an, Jiangsu Province, 223001, China.
Jiahuan ZhangDepartment of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510000, China.
Chongwen WangDepartment of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510000, China.
Bing GuDepartment of Clinical Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510000, China. gubing@gdph.org.cn.
Jiansong GuThe Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliate to Yangzhou University, Huai'an, Jiangsu Province, 223001, China. 876448066@qq.com.
Fen LiThe Fifth People's Hospital of Huai'an (Huai'an Hospital Affiliate to Yangzhou University, Huai'an, Jiangsu Province, 223001, China. 13776709866@163.com.

Funding

National Natural Science Foundation of China 82372348Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0532700
6 · The paper itself

Abstract

Rapid, sensitive, and low-cost in vitro screening is vital for controlling Helicobacter pylori (H. pylori) infection and guiding eradication, yet remains challenging. Here we report a high sensitivity lateral flow immunoassay (LFIA) based on a multifunctional composite magnetic-fluorescent probe (MTQD-Ab) that enables accurate detection of H. pylori in stool with minimal pretreatment and supports two modes-rapid screening and precise quantification-tailored to different use scenarios. The probe features a core-shell-biorecognition architecture: a 200 nm Fe

Indexed as

Fluorescent DyesHelicobacter pyloriAntibodies, ImmobilizedFecesHelicobacter InfectionsHumansImmunoassayLimit of DetectionMagnetite NanoparticlesQuantum DotsRapid Diagnostic TestsAntibodies, ImmobilizedFluorescent DyesMagnetite NanoparticlesDual-mode detectionDual signal amplificationH. pyloriLateral flow immunoassayMagnetic-fluorescent nanolabel

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.